IQVIA

Market Access

Innovative Medicines Fund and the opportunity for ICSs-indus...

In June 2022, NHS England (NHSE) and the National Institute for Health and Care Excellence (NICE) launched the Innovative Medicines Fund (IMF).

Market Access

Nine for 2023, part three: thriving or surviving?

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry

Patients

Nine for 2023, part two: healthcare’s hard problem, the prog...

The first part of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year,

Views & Analysis

Bringing the Benefits of eCOA BYOD Strategies to Clinical St...

Over the past few years, many clinical study administrators wanted to use the bring your own device (BYOD) model within their eCOA, but they were typically constrained by regulatory require

Patients